Postprandial Glycemic and GLP-1 Responses to Modified Full-sugar Drinks
Public ClinicalTrials.gov record NCT07918196. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This randomized, double-blind, crossover study will evaluate postprandial blood glucose and glucagon-like peptide-1 (GLP-1) responses to different sugar-containing beverages in healthy adults. The study will also evaluate whether the addition of epigallocatechin gallate (EGCG), a compound found in green tea, modifies glucose and GLP-1 responses. Participants will complete four study visits and consume a different study beverage at each visit. Blood samples will be collected to measure glucose, GLP-1, and insulin, and participants will complete questionnaires assessing satiety and sensory perception.
Study identification
- NCT ID
- NCT07918196
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 16 participants
Conditions and interventions
Conditions
Interventions
- Sucrose Beverage Dietary Supplement
- Glucose + Fructose beverage Dietary Supplement
- Sucrose with EGCG Beverage Dietary Supplement
- Glucose-Fructose with EGCG Beverage Dietary Supplement
Dietary Supplement
Eligibility (public fields only)
- Age range
- 18 Years to 45 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 21, 2026 (Actual)
- Primary completion
- Dec 2026 (Estimated)
- Completion
- Dec 2026 (Estimated)
- Last update posted
- Nov 5, 2026
2026
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Purdue Clinical Research Center (CRC) | West Lafayette | Indiana | 47907 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07918196, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 5, 2026 · Synced Nov 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07918196 live on ClinicalTrials.gov.